Compare Bank of Nova Scotia (BNS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Summit Therapeutics Inc — how do they compare? Bank of Nova Scotia trades at $90.32 (market cap $108.32B), while Summit Therapeutics Inc trades at $15.08 (market cap $12.06B). The key difference: Bank of Nova Scotia is far larger — about 9× Summit Therapeutics Inc's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BNS | SMMT | |
|---|---|---|
Market Cap | $108.32B | $12.06B |
Sector | Financials | Health |
52-Week High | $90.29 | $26.98 |
52-Week Low | $56.41 | $12.55 |
Dividend Yield | 3.64% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $89.92, up 1.54% with a bullish technical outlook supported by moving averages. The company demonstrates consistent earnings growth, beating estimates for three consecutive quarters with Q2 2026 expected at $1.53 EPS. Recent acquisition of MapleMark Bank and dividend increase to $1.14 highlight strategic growth initiatives. Valuation metrics show a P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a favorable investment case with analyst consensus leaning bullish (53% buy ratings) and technical indicators supporting upward momentum. Key opportunities include dividend growth, international expansion, and improving ROE at 11.87%. Risks include macroeconomic sensitivity, declining profit margins from 31.47% in 2022 to 20.99% in 2025, and elevated debt levels with $194.31 billion long-term obligations.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
